ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc.
Your view on PMN
Overview
What the company does, where it operates, and who runs it.
About ProMIS Neurosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neil K. Warma
- Headquarters
- 1920 Yonge Street, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neil K. Warma
- Headquarters
- 1920 Yonge Street, Toronto, ON, CA
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.
The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ProMIS Neurosciences, Inc., and the rating behind it. PMN last traded at $13.56; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ProMIS Neurosciences, Inc.. Starting points for ProMIS Neurosciences, Inc.: EPS -$4.62, beta -0.22 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ProMIS Neurosciences, Inc.. ProMIS Neurosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ProMIS Neurosciences, Inc.. Trailing twelve-month EPS for ProMIS Neurosciences, Inc. stands at -$4.62. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ProMIS Neurosciences, Inc.. ProMIS Neurosciences, Inc. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ProMIS Neurosciences, Inc. valued side by side against its closest peers. ProMIS Neurosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ProMIS Neurosciences, Inc., and how their positions are changing. At a $17.7M market value, institutional positions materially move ProMIS Neurosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ProMIS Neurosciences, Inc. executives and directors. Shares of ProMIS Neurosciences, Inc. have traded between $0.35 and $1.59 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ProMIS Neurosciences, Inc.. ProMIS Neurosciences, Inc. is a $17.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ProMIS Neurosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ProMIS Neurosciences, Inc.. Coverage tracks ProMIS Neurosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.